Bryan Garnier - TESCO (TSCO) Tesco: H1 EBIT beat and a welcome FY EBIT guidance upgrade

Report

Bryan Garnier

Clement Genelot

Tesco: H1 EBIT beat and a welcome FY EBIT guidance upgrade

Post Tesco's strong set of H1 figures (particularly EBIT while sales were just in line), we view the FY retail EBIT guidance upgrade to "around GBP2.9bn" as sufficient enough to please investors and prompt a few estimates upgrades among sell-side analysts. Tesco's exposure to the healthy UK market

03/10/2024 1 EN

Underlying

TESCO

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Clement Genelot

Other Reports on these Companies

Bryan Garnier

On the shelves now: Consumer weekly #39

In this Consumer Weekly newsletter, we provide a brief overview of the key factors affecting our Consumer coverage, from Luxury & Consumer goods to Retail & E-commerce and Food & Ingredients. This week, we discuss the Fed's upcoming meeting and rate cut. Happy reading!

September 16, 2024 September 16, 2024 1 EN

Bryan Garnier

Tesco: defensive appeal and earnings momentum overshadow stretched valuation

Ahead of the H1 release on 3rd October, we have lifted our FY FCF by c.3% and our PT from 349p to 386p on the back of better market dynamics and Tesco's market share development. While acknowledging the stretched valuation, we continue to favour Tesco (Buy) alongside Ahold Delhaize (Buy) as a conti

September 12, 2024 September 12, 2024 1 EN

Abivax: Obefazimod in Crohn's disease clinical development

Abivax announced the start of clinical investigations in Crohn’s disease (CD) with obefazimod, disclosing the enrolment of the first patient. This phase IIb study (NCT06456593) named ENHANCE-CD is a multicentre, double-blind, randomized, placebo-controlled trial, with a design comparable to the com

10h / 10m 10h / 10m 1 EN

Bruno Bulic

Bruno Bulic

Abivax positive long-term Ph. II data

Abivax announced excellent interim data on the long-term open-label extension phase of it’s Ph. IIb at a reduced 25mg dose od (versus 50mg od in Ph. IIb). In this extension study, patients who completed the 4-year Ph. IIa or 2-year Ph. IIb with 50mg obefazimod with clinical response could enter thi

October 3, 2024 October 3, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Tesco: H1 EBIT beat and a welcome FY EBIT guidance upgrade

On the shelves now: Consumer weekly #39

Tesco: defensive appeal and earnings momentum overshadow stretched valuation

Abivax: Obefazimod in Crohn's disease clinical development

Abivax positive long-term Ph. II data

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe